|
|
 Previous Article | Table of Contents | Next Article 
Alteration of fibrin network by activated protein C
A Gruber, E Mori, GJ del Zoppo, L Waxman and JH Griffin
Department of Molecular and Experimental Medicine, Scripps Research
Institute, La Jolla, CA 92037.
The antithrombotic plasma enzyme, activated protein C (APC), may play a
role in thrombolysis. In vitro, acceleration of clot lysis by APC depends
on its ability to inhibit the activation of prothrombin. The effect of APC
on the assembly and dispersion of fibrin network was studied using
turbidimetry, plasmin digestion of fibrin, and electron microscopy of
plasma clots. The addition of APC before clotting but not after clotting
accelerated clot lysis. The rate of increase in the turbidity of clotting
plasma was reduced by APC. The turbidity of plasma clots containing APC was
directly related to the clot lysis time. Fibrin from plasma clots that were
formed in the presence of APC yielded less fibrin degradation products than
fibrin from clots without added APC. Furthermore, APC reduced the diameter
and relative number of fibrin fibers in plasma clots during gel assembly.
We propose that APC may enhance the efficacy of thrombolysis by reducing
the relative mass of fibrin within maturing thrombi.
Volume 83,
Issue 9,
pp. 2541-2548,
05/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. A. Smith and J. H. Morrissey
Polyphosphate enhances fibrin clot structure
Blood,
October 1, 2008;
112(7):
2810 - 2816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Carter, C. M. Cymbalista, T. D. Spector, P. J. Grant, and on behalf of the EuroCLOT Investigators
Heritability of Clot Formation, Morphology, and Lysis: The EuroCLOT Study
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2007;
27(12):
2783 - 2789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Hafer-Macko, F. M. Ivey, J. D. Sorkin, and R. F. Macko
Microvascular tissue plasminogen activator is reduced in diabetic neuropathy
Neurology,
July 17, 2007;
69(3):
268 - 274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Sajan, S. S. Da-Silva, and R. P. Dellinger
Drotrecogin Alfa (Activated) in an Infant with Gram-Negative Septic Shock
J Intensive Care Med,
January 1, 2004;
19(1):
51 - 55.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Niessen, T. Hilger, M. Hoehn, and K.-A. Hossmann
Differences in Clot Preparation Determine Outcome of Recombinant Tissue Plasminogen Activator Treatment in Experimental Thromboembolic Stroke
Stroke,
August 1, 2003;
34(8):
2019 - 2024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Wolberg, D. M. Monroe, H. R. Roberts, and M. Hoffman
Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk
Blood,
April 15, 2003;
101(8):
3008 - 3013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Hafer-Macko, F. M. Ivey, K. A. Gyure, J. D. Sorkin, and R. F. Macko
Thrombomodulin Deficiency in Human Diabetic Nerve Microvasculature
Diabetes,
June 1, 2002;
51(6):
1957 - 1963.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Sheiman and D. P. Brophy
Treatment of Iatrogenic Femoral Pseudoaneurysms with Percutaneous Thrombin Injection: Experience in 54 Patients
Radiology,
April 1, 2001;
219(1):
123 - 127.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K S Nair, A Weerasinghe, M Dahdal, J S. R Gibbs, and J R Anderson
Cardiac intraventricular thrombus in protein C deficiency
J R Soc Med,
January 12, 2001;
94(12):
641 - 642.
[Full Text]
[PDF]
|
|
|
|
|
